Research
Continuing advanced therapies before elective Crohn's surgery may reduce serious complications
The Brief
- Patients with Crohn's disease who continue advanced therapies such as biologics and small-molecule drugs before elective colorectal surgery may have a lower risk of certain postoperative complications.
- The two complications named in the source are anastomotic leak and organ space surgical site infection.
- The source reports an association, not a proven causal effect of continuing therapy.
Why it matters
For clinicians and researchers treating Crohn's disease, the findings suggest that perioperative drug management may influence surgical outcomes, which could inform future guidance on whether to continue or pause advanced therapies before elective surgery.
Who’s affected
- patients with Crohn's disease facing elective colorectal surgery
- gastroenterologists and colorectal surgeons
- #crohn's disease
- #colorectal surgery
- #biologics
- #surgical complications
- #inflammatory bowel disease
Patients with Crohn's disease who continue advanced therapies, including biologics and small-molecule drugs, in the months before elective colorectal surgery may have a lower risk of two postoperative complications: anastomotic leak and organ space surgical site infection…